RecruitingPhase 1NCT03900793
Losartan + Sunitinib in Treatment of Osteosarcoma
Studying Osteosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Colorado, Denver
- Principal Investigator
- Kelly Faulk, MD, MDChildren's Hospital Colorado
- Intervention
- Losartan(drug)
- Enrollment
- 41 target
- Eligibility
- 10 years · All sexes
- Timeline
- 2019 – 2027
Study locations (4)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- University of Colorado Hospital, Aurora, Colorado, United States
- Children's Hospital of Atlanta, Atlanta, Georgia, United States
Collaborators
Cancer League of Colorado · Colorado State University · Swim Across America
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03900793 on ClinicalTrials.govOther trials for Osteosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502885Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer PatientsSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07477457A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06492954Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaEmory University
- RECRUITINGNANCT07129226Musculoskeletal Cancers Remote Monitoring and CareCase Comprehensive Cancer Center
- RECRUITINGPHASE1NCT07144254Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaEmory University
- RECRUITINGPHASE1NCT07227571Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe TrialFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT07193550A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)M.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT07052383Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue SarcomasTcelltech Inc.